Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

We had not assumed this proposed rule would pass, and we continue to think Novo and Lilly will gain Medicare obesity drug coverage via overlapping indications with time, such as Zepbound’s ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage of anti-obesity drugsThe Trump administration says it will ...

confirmed that it will not proceed with a Biden administration proposal to expand Medicare coverage for anti-obesity drugs ...

However, a spokesperson for Novo Nordisk implied the Danish drugmaker plans to continue lobbying for expanded Medicare ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...

The Centers for Medicare and Medicaid Services issued ... $620 and maintaining our DKK 640/$89 fair value estimate for Novo Nordisk. We had not assumed this proposed rule would pass, and we ...